Treatment patterns in patients with castration-resistant prostate cancer who received darolutamide in the ARAMIS trial in Spain: PARASEC study
{{output}}
Purpose: We aimed to describe treatment patterns of patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) who progressed after receiving darolutamide in a real-world setting, and according to the standard clin... ...
